[ TRANSACTION RECORD ]

JPMorgan Chase & Co. Investment in ImmunoGen Inc. — 2023

VERIFIED VECTOR ID: 002136 · tx-232
M SOURCE NODE — FUNDER
JPMorgan Chase & Co.
Finance United States
$10,100,000,000
EQUITY
30/11/2023
Q DESTINATION NODE — RECIPIENT
ImmunoGen Inc.
Company United States
Amount (USD)
$10.1B
Flow Type
EQUITY
Transaction Date
30/11/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity JPMorgan Chase & Co.
AUM 3900000
HQ Location United States
Sector Finance
Recipient Profile [ Q ]
Entity ImmunoGen Inc.
Entity Type Company
Jurisdiction United States
Intelligence Note

AbbVie Inc. announced the acquisition of ImmunoGen for 10.1 billion dollars to bolster its oncology pipeline with a leading antibody-drug conjugate for ovarian cancer treatment. This transaction provides AbbVie with a commercially available targeted therapy. The deal is a significant strategic investment in the next generation of precision cancer medicine.

Σ
Primary Forensic Source https://news.abbvie.com/2023-11-30-AbbVie-to-Acquire-ImmunoGen/
✓ SOURCE LINKED